Krystal Biotech, Inc. (KRYS)

369.38 +5.54 (+1.52%) USD  |  NASDAQ  |  Sep 02, 16:00
369.38 0.00 (0.00%) After-Hours: 20:00
More

Krystal Biotech Research and Development Expense (Annual) : 52.32M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for KRYS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 2016. Start Trial.
Date Value
December 31, 2025 52.32M
December 31, 2024 53.57M
December 31, 2023 46.43M
December 31, 2022 39.86M
December 31, 2021 26.08M
Date Value
December 31, 2020 17.94M
December 31, 2019 15.62M
December 31, 2018 7.761M
December 31, 2017 3.208M
December 31, 2016 0.741M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Marker Therapeutics, Inc. 11.80M
TG Therapeutics, Inc. 160.22M
Cytokinetics, Inc. 405.90M
ADMA Biologics, Inc. 4.762M
Alnylam Pharmaceuticals, Inc. 1.320B